Adjuvant pembrolizumab gets positive opinion from the European CHMP
We have just learnt that the Committee for Medicinal Products [...]
Cancer clinical trial recruitment drops by 60% during the pandemic
Hospital Pharmacy Europe reported that the number of cancer patients [...]
First-line nivolumab plus ipilimumab in kidney cancer patients without nephrectomy
A recent post hoc analysis of the CheckMate 214 trial [...]
Cabozantinib after progression of kidney cancer improves survival
In a recent study, the use of cabozantinib after progression [...]
FDA approves adjuvant pembrolizumab for intermediate-high risk kidney cancer
The Food and Drug administration (FDA) in the USA has [...]
Metastasectomy in kidney cancer
A recent review published in Current Opinion in Supportive and [...]
Immunotherapy combinations in the first-line treatment of metastatic sarcomatoid kidney cancer
A recent study looked at the efficacy and safety of [...]
Updates to the European Association of Urology (EAU) Guidelines for Renal Cell Carcinoma
The European Association of Urology (EAU) Guidelines for Renal Cell [...]
International Kidney Cancer Symposium (IKCS) 2021
The International Kidney Cancer Symposium (IKCS) 2021 took place in [...]
Risks and benefits of adjuvant therapy for kidney cancer
Treatment of people with intermediate to high risk renal cell [...]
